You are here: Industry Insights > XBiotech

News List

XBiotech Announces Dividend to Holders of Common Stock firstwordpharma
July 07, 2021
XBiotech Inc.'s (NASDAQ: XBIT) ("XBiotech") Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock.
XBiotech and BioBridge to develop plasma-based Covid-19 therapy pharmaceutical-technology
April 07, 2020
Biopharmaceutical firm XBiotech has partnered with non-profit BioBridge Global to develop a Covid-19 therapy using natural antibodies from convalescent plasma of recovered patients.
Janssen Completes Acquisition of Investigational Bermekimab from XBiotech americanpharmaceuticalreview
January 06, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees ...
XBiotech to sell anti- IL-1⍺ antibody bermekimab to Janssen in $1.3bn deal pharmaceutical-business-review
December 11, 2019
XBiotech has agreed to offload its human antibody bermekimab to Janssen Biotech, a subsidiary of Janssen Pharmaceutical Company of Johnson & Johnson, in a deal worth up to $1.35bn.
Janssen to acquire bermekimab’s rights from XBiotech for $750m pharmaceutical-technology
December 10, 2019
Janssen Biotech has signed a definitive agreement to buy rights to XBiotech’s investigational monoclonal antibody, bermekimab, for a cash consideration of $750m.